|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
LY6K is a cancer biomarker and a therapeutic target that induces invasion and metastasis.
|
22988241 |
2012 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
LY6K is a cancer biomarker and a therapeutic target that induces invasion and metastasis.
|
22988241 |
2012 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
LY6K is a cancer biomarker and a therapeutic target that induces invasion and metastasis.
|
22988241 |
2012 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Cell viability assays demonstrated that significant inhibitions of cell growth, migration, and invasion occured in LY6K knock down BC cell lines; converse phenomena were observed in a stable LY6K transfectant; and LY6K knockdown of the transfectant retrieved the original phenotype from the LY6K transfectant.
|
21063397 |
2011 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In addition, LY-6K caused cancer cell metastasis and it is linked to the Ras/ERK signaling pathway.
|
19639180 |
2009 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that LY-6K meaningfully participates in breast cancer cell metastasis by influencing cell migration and invasion through the Ras/ERK pathway.
|
19639180 |
2009 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
In addition, LY-6K caused cancer cell metastasis and it is linked to the Ras/ERK signaling pathway.
|
19639180 |
2009 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
For the development of cancer vaccine therapies, we have searched for possible epitope peptides that can elicit cytotoxic T lymphocytes (CTL) to the TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K) and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3), which were previously identified to be transactivated in the majority of lung and esophageal cancers.
|
17784873 |
2007 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In most cases, there was no correlation between serum LY6K and conventional tumor markers of carcinoembryonic antigen (CEA) and cytokeratin 19-fragment (CYFRA 21-1) values.
|
18089789 |
2007 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
For the development of cancer vaccine therapies, we have searched for possible epitope peptides that can elicit cytotoxic T lymphocytes (CTL) to the TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K) and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3), which were previously identified to be transactivated in the majority of lung and esophageal cancers.
|
17784873 |
2007 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
LY6K (lymphocyte antigen 6 complex locus K), FAM83A (family member with sequence similarity 83), CELSR3, ASF1B, IQGAP3, SEMA3F, CLDN10, MSX1, CXCL5, ASRGL1, ELAVL2, GRB7, KHSRP, NOVA1, PTBP1, and RNASEH2A were identified as novel candidate genes associated with cervical lesion progression and carcinogenesis.
|
30696738 |
2019 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Five potential feature genes, S100A4, ECE2, CAST, ASPH, and LY6K, were discovered after network mining as well as correlation analysis between AS and gene expression, most of which were related to carcinogenesis and development.
|
31608231 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
LY6K protein and mRNA level expressions were increased in NSCLC patients.
|
30249107 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We established an ELISA to measure serum LY6K and found that the proportion of the serum LY6K-positive cases was 38 of 112 (33.9%) NSCLC and 26 of 81 (32.1%) ESCC, whereas only 3 of 74 (4.1%) healthy volunteers were falsely diagnosed.
|
18089789 |
2007 |
|
Esophageal Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In addition, knocked down of LY6K expression with small interfering RNAs resulted in growth suppression of the lung and esophageal cancer cells.
|
18089789 |
2007 |
|
Esophageal Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our results strongly imply that TTK, LY6K and IMP-3 are novel tumor-associated antigens recognized by CTL, and TTK-567 (SYRNEIAYL), LY6K-177 (RYCNLEGPPI) and IMP-3-508 (KTVNELQNL) are HLA-A24-restricted epitope peptides that can induce potent and specific immune responses against lung and esophageal cancer cells expressing TTK, LY6K and IMP-3.
|
17784873 |
2007 |
|
Esophageal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results strongly imply that TTK, LY6K and IMP-3 are novel tumor-associated antigens recognized by CTL, and TTK-567 (SYRNEIAYL), LY6K-177 (RYCNLEGPPI) and IMP-3-508 (KTVNELQNL) are HLA-A24-restricted epitope peptides that can induce potent and specific immune responses against lung and esophageal cancer cells expressing TTK, LY6K and IMP-3.
|
17784873 |
2007 |
|
Esophageal carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, knocked down of LY6K expression with small interfering RNAs resulted in growth suppression of the lung and esophageal cancer cells.
|
18089789 |
2007 |
|
Malignant neoplasm of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results strongly imply that TTK, LY6K and IMP-3 are novel tumor-associated antigens recognized by CTL, and TTK-567 (SYRNEIAYL), LY6K-177 (RYCNLEGPPI) and IMP-3-508 (KTVNELQNL) are HLA-A24-restricted epitope peptides that can induce potent and specific immune responses against lung and esophageal cancer cells expressing TTK, LY6K and IMP-3.
|
17784873 |
2007 |
|
Malignant neoplasm of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, knocked down of LY6K expression with small interfering RNAs resulted in growth suppression of the lung and esophageal cancer cells.
|
18089789 |
2007 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Phenotypic patterns were determined by immunohistochemistry (IHC) of pathological samples from patients with HIV-associated DLBCL prospectively enrolled in the French AIDS and Viral Hepatitis CO16 Lymphovir cohort between 2008 and 2015.
|
31468517 |
2020 |
|
Lymphoma, AIDS-Related
|
0.010 |
Biomarker
|
disease |
BEFREE |
We evaluated the associations between HCV, HBV and HIV-related lymphomas in the Lymphovir-ANRS-CO16 cohort.
|
31833850 |
2020 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The functions of miR-500a-3p and LY6K in proliferation/invasion and lung metastasis formation were assessed by CCK8, Transwell assay and subcutaneous tumor model in nude mice, respectively.
|
30249107 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs.
|
29568993 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs.
|
29568993 |
2018 |